Turning point in COVID-19 severity and fatality during the pandemic: a national cohort study in Qatar
Author | Chemaitelly, Hiam |
Author | Ayoub, Houssein H |
Author | Faust, Jeremy Samuel |
Author | Coyle, Peter |
Author | Tang, Patrick |
Author | Hasan, Mohammad R |
Author | Yassine, Hadi M |
Author | Al-Khatib, Hebah A |
Author | Al Thani, Asmaa A |
Author | Al-Kanaani, Zaina |
Author | Al-Kuwari, Einas |
Author | Jeremijenko, Andrew |
Author | Kaleeckal, Anvar Hassan |
Author | Latif, Ali |
Author | Shaik, Riyazuddin Mohammad |
Author | Abdul-Rahim, Hanan F |
Author | Nasrallah, Gheyath K |
Author | Al-Kuwari, Mohamed Ghaith |
Author | Butt, Adeel Ajwad |
Author | Al-Romaihi, Hamad |
Author | Al-Thani, Mohamed H |
Author | Al-Khal, Abdullatif |
Author | Bertollini, Roberto |
Author | Abu-Raddad, Laith J |
Available date | 2023-11-06T05:28:46Z |
Publication Date | 2023-05 |
Publication Name | BMJ Public Health |
Identifier | http://dx.doi.org/10.1136/bmjph-2023-000479 |
Citation | Chemaitelly H, Ayoub HH, Faust JS, et alTurning point in COVID-19 severity and fatality during the pandemic: a national cohort study in QatarBMJ Public Health 2023;1:e000479. doi: 10.1136/bmjph-2023-000479 |
Abstract | Objective To assess the evolution of COVID-19 severity and fatality in a unique setting that consistently applied, throughout the pandemic, rigorous and standardised criteria for defining severe COVID-19 outcomes. Methods and analysis We conducted a national cohort study on 312 109 Qatari citizens to investigate incidence of severe, critical or fatal COVID-19 classified according to the WHO criteria between 28 February 2020 and 21 April 2023. Incidence rates for severe, critical or fatal COVID-19 were estimated during the pre-omicron phase, first omicron wave, combined phases and throughout the pandemic. Results Cumulative incidence of severe, critical or fatal COVID-19 after 3.14 years of follow-up was 0.45% (95% CI 0.43% to 0.47%). Incidence rate for severe, critical or fatal COVID-19 throughout the pandemic was 1.43 (95% CI 1.35 to 1.50) per 1000 person years. In the pre-omicron phase, first omicron wave, and combined phases, it was 2.01 (95% CI 1.90 to 2.13), 3.70 (95% CI 3.25 to 4.22) and 2.18 (95% CI 2.07 to 2.30) per 1000 person years, respectively. The post-first omicron phase saw a drastic drop to 0.10 (95% CI 0.08 to 0.14) per 1000 person years, a 95.4% reduction. Among all severe, critical and fatal cases, 99.5% occurred during the primary infection. Cumulative incidence of fatal COVID-19 was 0.042% (95% CI 0.036% to 0.050%), with an incidence rate of 0.13 (95% CI 0.11 to 0.16) per 1000 person years. In the post-first omicron phase, incidence rate of fatal COVID-19 decreased by 90.0% compared with earlier stages. Both severity and fatality exhibited an exponential increase with age and a linear increase with the number of coexisting conditions. Conclusion The conclusion of the first omicron wave was a turning point in the severity of the pandemic. While vaccination and enhanced case management reduced severity gradually, the rapid accumulation of natural immunity during the first omicron wave appears to have played a critical role in driving this shift in severity. |
Sponsor | This work was possible through institutional salary support from the Biomedical Research Program and the Biostatistics, Epidemiology, and Biomathematics Research Core, both at Weill Cornell Medicine-Qatar, as well as institutional salary support provided by the Ministry of Public Health, Hamad Medical Corporation and Sidra Medicine. The authors are also grateful for the Qatar Genome Programme and Qatar University Biomedical Research Center for institutional support for the reagents needed for the viral genome sequencing. HHA acknowledges the support of Qatar University Internal Grant ID QUCG-CAS-23/24-114. |
Language | en |
Publisher | BMJ Publishing Group |
Subject | COVID-19 severity fatality turning point |
Type | Article |
Issue Number | 1 |
Volume Number | 1 |
ESSN | 2753-4294 |
Files in this item
This item appears in the following Collection(s)
-
Biomedical Research Center Research [738 items ]
-
Biomedical Sciences [738 items ]
-
COVID-19 Research [835 items ]
-
Mathematics, Statistics & Physics [740 items ]
-
Public Health [431 items ]